Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.07. | Psyence Group Inc (2): Psyence closes $124,000 second tranche of placement | 1 | Stockwatch | ||
PSYENCE GROUP Aktie jetzt für 0€ handeln | |||||
07.07. | Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds | 361 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / July 7, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), is pleased to announce that it has successfully closed the second tranche ("Tranche 2") of... ► Artikel lesen | |
26.06. | Psyence Group Inc (2): Psyence closes $476,000 first tranche of financing | 1 | Stockwatch | ||
25.06. | PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares | 1 | GlobeNewswire (USA) | ||
19.06. | Psyence Group Inc (2): Psyence Group arranges $600,000 private placement | 1 | Stockwatch | ||
18.06. | Psyence Group announces offering of up to C$600,000 non-brokered private placement of common shares | 1 | Seeking Alpha | ||
18.06. | PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares | 1 | GlobeNewswire (USA) | ||
23.04. | XFRA 8VC0,BC21,EKW0,1S90: AUSSETZUNG/SUSPENSION | 168 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILGREAT PLAINS MET.... ► Artikel lesen | |
23.04. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.04.2025 | 324 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.04.2025
Aktien
1 US7866231084 AB Sagax ADR
2 US36170Y1038... ► Artikel lesen | |
22.04. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.04.2025 | 406 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.04.2025ISIN NameCA00833F3079 AFRICAN... ► Artikel lesen | |
22.04. | XFRA ISIN CHANGE | 399 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA00833F3079 African Energy Metals Inc. 22.04.2025 CA5589221004 Magma Silver Corp. 23.04.2025 Tausch 1:1CA74449Q1063 Psyence... ► Artikel lesen | |
22.04. | CSE Bulletin: Consolidation - Psyence Group Inc. (PSYG) | 348 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 21 avril/April 2025) - Psyence Group Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated... ► Artikel lesen | |
21.04. | Psyence Group Inc: Psyence Group 1:15 rollback | 2 | Stockwatch | ||
17.04. | Psyence Group announces share consolidation | 1 | Seeking Alpha | ||
17.04. | Psyence Group Inc.: Psyence Group Announces Share Consolidation | 179 | GlobeNewswire (Europe) | TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share... ► Artikel lesen | |
09.04. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 09.04.2025 | 808 | Xetra Newsboard | The following instruments on XETRA do have their first trading 09.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 09.04.2025
Aktien
1 US83192D4025 Smartstop Self Storage... ► Artikel lesen | |
25.03. | Psyence Group Inc: Psyence associate appoints Stein to advisory board | 1 | Stockwatch | ||
25.03. | Psyence Group Inc.: Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein | 1 | GlobeNewswire (USA) | ||
10.03. | Psyence Group Inc: Psyence associate adds Garcia-Romeu as chair of SAB | 1 | Stockwatch | ||
10.03. | Psyence Group announces collaboration with Johns Hopkins researcher | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,760 | -3,42 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen vor Quartalszahlen des Diagnostik-Unternehmens auf "Buy" mit einem Kursziel von 50 Euro belassen. Die ersten Quartalsergebnisse... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 48,290 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
CG ONCOLOGY | 25,290 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 52,76 | -1,22 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
DYNE THERAPEUTICS | 11,615 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
BIONTECH | 95,65 | +0,10 % | BionTech mit voller Kriegskasse! | BionTech mit voller Kriegskasse ► Artikel lesen | |
EVOTEC | 6,506 | -2,90 % | KI und BioTech - Ein Traumpaar für Rendite! Evotec und Novo Nordisk im Rampenlicht, NetraMark gibt Gas! | Der Biotech-Sektor durchläuft derzeit einen tiefgreifenden Wandel: Big Data und Künstliche Intelligenz revolutionieren die Art und Weise, wie Medikamente erforscht und entwickelt werden. KI-gestützte... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 16,310 | -2,22 % | Structure Therapeutics reports Q2 results | ||
Y-MABS THERAPEUTICS | 8,515 | -0,06 % | Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition | ||
AINOS | 3,300 | 0,00 % | Ainos, Inc.: Ainos Secures $2.1 Million Order With ASE Technology for First Deployment of AI Nose in Semiconductor Manufacturing Setting | First Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial ApplicationsAinos Building Commercial Momentum with Multi-Site Deployments Underway in Japan and Taiwan SAN... ► Artikel lesen | |
ADMA BIOLOGICS | 18,560 | 0,00 % | ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth | ||
DAY ONE BIOPHARMACEUTICALS | 5,830 | -15,26 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
JANUX THERAPEUTICS | 24,165 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
NOVAVAX | 6,450 | -0,89 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen |